Literature DB >> 28752236

Opa interacting protein 5 acts as an oncogene in bladder cancer.

Xuefeng He1, Jianquan Hou1, Jigen Ping1, Duangai Wen2, Jun He3.   

Abstract

PURPOSE: To explore the biological functions and mechanism of Opa interacting protein 5 (OIP5) in bladder cancer (BC).
METHODS: We investigated the expression of OIP5 in BC through immunohistochemical staining (IHC) and its correlation with clinicopathologic features of BC patients. Moreover, knockdown of OIP5 was performed in BC cell lines and colony formation capacity, cell growth curve, cell cycle phase and cell apoptosis assay was applied for investigating the roles of OIP5 in BC. Moreover, the expression of OIP5 was validated through the Cancer Genome Atlas (TCGA) database. The diagnosis value of OIP5 was accessed by receiver operating characteristic (ROC) analysis in TCGA database.
RESULTS: The expression of OIP5 in BC tissues was significantly higher than that in adjacent non-tumor tissues and bladder mucosa tissues with chronic cystitis. Higher protein expression level of OIP5 predicted shorter survival time in patients with BC, which was significantly correlated with larger tumor size, high-grade tumor and advanced T classification. The expression of OIP5 was considerably decreased after lentivirus infection both at mRNA and protein levels. Functional assay displayed that silencing of OIP5 inhibited colony formation capacity and cell growth in BC cell lines. Cell cycle assays indicated that suppressed OIP5 disturbed the balance of the cell cycle in BC cell lines, which increased the cell population of the G1 phase and decreased the cell population of the S phase. Furthermore, knockdown of OIP5 expression enhanced cell apoptosis process. The expression of OIP5 was significantly up-regulated in BC compared with adjacent non-tumor tissues based on TCGA database. OIP5 had the potential diagnostic value for BC.
CONCLUSIONS: Our work demonstrated that OIP5 might function as an oncogene to promote colony formation capacity and cell growth, arrest cell cycle and suppress cell apoptosis in bladder cancer.

Entities:  

Keywords:  Cell apoptosis; Cell cycle; Cell growth; OIP5 protein; Urinary bladder neoplasm

Mesh:

Substances:

Year:  2017        PMID: 28752236     DOI: 10.1007/s00432-017-2485-4

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  30 in total

1.  International variations in bladder cancer incidence and mortality.

Authors:  Saurabh Chavan; Freddie Bray; Joannie Lortet-Tieulent; Michael Goodman; Ahmedin Jemal
Journal:  Eur Urol       Date:  2013-10-16       Impact factor: 20.096

2.  Using the yeast two-hybrid system to identify human epithelial cell proteins that bind gonococcal Opa proteins: intracellular gonococci bind pyruvate kinase via their Opa proteins and require host pyruvate for growth.

Authors:  J M Williams; G C Chen; L Zhu; R F Rest
Journal:  Mol Microbiol       Date:  1998-01       Impact factor: 3.501

3.  Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches.

Authors:  Jochen Greiner; Michael Schmitt; Li Li; Krzysztof Giannopoulos; Katrin Bosch; Anita Schmitt; Konstanze Dohner; Richard F Schlenk; Jonathan R Pollack; Hartmut Dohner; Lars Bullinger
Journal:  Blood       Date:  2006-08-24       Impact factor: 22.113

Review 4.  Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.

Authors:  Samuel A Funt; Jonathan E Rosenberg
Journal:  Nat Rev Clin Oncol       Date:  2016-11-22       Impact factor: 66.675

5.  Expression analysis of four testis-specific genes AURKC, OIP5, PIWIL2 and TAF7L in acute myeloid leukemia: a gender-dependent expression pattern.

Authors:  Fatemeh Yazarloo; Reza Shirkoohi; Maryam Beigom Mobasheri; Amirhossein Emami; Mohammad Hossein Modarressi
Journal:  Med Oncol       Date:  2013-01-06       Impact factor: 3.064

6.  Down-regulation of cancer/testis antigen OY-TES-1 attenuates malignant behaviors of hepatocellular carcinoma cells in vitro.

Authors:  Jun Fu; Bin Luo; Wen-Wen Guo; Qing-Mei Zhang; Lei Shi; Qi-Ping Hu; Fang Chen; Shao-Wen Xiao; Xiao-Xun Xie
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

7.  MAGE-A10 cancer/testis antigen is highly expressed in high-grade non-muscle-invasive bladder carcinomas.

Authors:  Chantal Mengus; Elke Schultz-Thater; Julie Coulot; Zeljko Kastelan; Eleonora Goluza; Marijana Coric; Giulio C Spagnoli; Tvrtko Hudolin
Journal:  Int J Cancer       Date:  2012-11-16       Impact factor: 7.396

8.  LAP2alpha-binding protein LINT-25 is a novel chromatin-associated protein involved in cell cycle exit.

Authors:  Nana Naetar; Sabine Hutter; Daniela Dorner; Thomas Dechat; Barbara Korbei; Josef Gotzmann; Hartmut Beug; Roland Foisner
Journal:  J Cell Sci       Date:  2007-02-06       Impact factor: 5.285

9.  FOXD3 is a tumor suppressor of colon cancer by inhibiting EGFR-Ras-Raf-MEK-ERK signal pathway.

Authors:  Kun Li; Qunfeng Guo; Jun Yang; Hui Chen; Kewen Hu; Juan Zhao; Shunxin Zheng; Xiufeng Pang; Sufang Zhou; Yongyan Dang; Lei Li
Journal:  Oncotarget       Date:  2017-01-17

Review 10.  Modifiable risk factors for the prevention of bladder cancer: a systematic review of meta-analyses.

Authors:  Abdulmohsen H Al-Zalabani; Kelly F J Stewart; Anke Wesselius; Annemie M W J Schols; Maurice P Zeegers
Journal:  Eur J Epidemiol       Date:  2016-03-21       Impact factor: 8.082

View more
  9 in total

1.  Expression profile of ACTL8, CTCFL, OIP5 and XAGE3 in glioma and their prognostic significance: a retrospective clinical study.

Authors:  Xisheng Li; Lidong Ning; Qingmei Zhang; Yingying Ge; Chang Liu; Shuiqing Bi; Xia Zeng; Weixia Nong; Song Wu; Gaoshui Guo; Shaowen Xiao; Bin Luo; Xiaoxun Xie
Journal:  Am J Transl Res       Date:  2020-12-15       Impact factor: 4.060

2.  Lentivirus-mediated shRNA targeting MUTYH inhibits malignant phenotypes of bladder cancer SW780 cells.

Authors:  Qunjun Gao; Yuhan Liu; Haibiao Xie; Yucheng Zhong; Xinhui Liao; Hengji Zhan; Qun Zhou; Mengting Ding; Kang Yang; Aolin Li; Yuchen Liu; Hongbing Mei; Zhiming Cai
Journal:  Onco Targets Ther       Date:  2018-09-21       Impact factor: 4.147

3.  Identification of an eight-gene prognostic signature for lung adenocarcinoma.

Authors:  Shicheng Li; Yunpeng Xuan; Bing Gao; Xiao Sun; Shuncheng Miao; Tong Lu; Yuanyong Wang; Wenjie Jiao
Journal:  Cancer Manag Res       Date:  2018-09-10       Impact factor: 3.989

4.  Overexpression of Opa interacting protein 5 increases the progression of liver cancer via BMPR2/JUN/CHEK1/RAC1 dysregulation.

Authors:  Yuwen Li; Fei Xiao; Wenting Li; Pingping Hu; Ruirui Xu; Jun Li; Guimei Li; Chuanlong Zhu
Journal:  Oncol Rep       Date:  2019-02-11       Impact factor: 3.906

5.  Identification and validation of key genes with prognostic value in non-small-cell lung cancer via integrated bioinformatics analysis.

Authors:  Li Wang; Jialin Qu; Yu Liang; Deze Zhao; Faisal Ul Rehman; Kang Qin; Xiaochun Zhang
Journal:  Thorac Cancer       Date:  2020-02-14       Impact factor: 3.500

6.  OIP5 Is a Novel Prognostic Biomarker in Clear Cell Renal Cell Cancer Correlating With Immune Infiltrates.

Authors:  Mancheng Gong; Yongxiang Li; Erlin Song; Miaoyuan Li; Shaopeng Qiu; Wenjing Dong; Runqiang Yuan
Journal:  Front Immunol       Date:  2022-02-15       Impact factor: 7.561

7.  Opa-Interacting Protein 5 Expression in Human Glioma Tissues Is Essential to the Biological Function of U251 Human Malignant Glioma Cells.

Authors:  Libo Chen; Ruizhi Wang; Ligui Gao; Wei Shi
Journal:  Cancer Control       Date:  2020 Jan-Dec       Impact factor: 3.302

Review 8.  Long non-coding RNA OIP5-AS1 (Cyrano): A context-specific regulator of normal and disease processes.

Authors:  Serena Wooten; Keriayn N Smith
Journal:  Clin Transl Med       Date:  2022-01

9.  A chromatin-associated splicing isoform of OIP5-AS1 acts in cis to regulate the OIP5 oncogene.

Authors:  Elżbieta Wanowska; Magdalena Kubiak; Izabela Makałowska; Michał Wojciech Szcześniak
Journal:  RNA Biol       Date:  2021-01-20       Impact factor: 4.652

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.